Pseudoephedrine News and Research

RSS

Strong opposition to 'prescription-only' measures for OTC medicines with pseudoephedrine

More than 300 million Americans get the common cold, and up to 70 million get the flu annually. But for the 60 million people who also have asthma and allergies, a cold or flu can pose even greater risks. Together, these respiratory diseases take a devastating toll on public health, costing billions of dollars in direct medical expenses, reducing quality of life, lowering workplace and school performance, and can even be life-threatening to high-risk populations, such as asthma patients.

25 Jan 2011

Maine has most improved health care quality; Kansas needs more dentists

Maine Public Broadcasting Network News: "Nationwide, Maine is most improved when it comes to health care quality, according to 2009 statistics from the federal Agency for Healthcare Research and Quality. In one year, Maine jumped from 12th place to fourth best in categories ranging from cancer to patient safety, from maternal and child health to long-term care.

17 Nov 2010

FDA grants Impax final approval for generic Allegra-D ANDA

Impax Laboratories, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted final approval of the Company's Abbreviated New Drug Application (ANDA) for the generic version of Allegra-D® (Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended-release) 60mg/120mg tablets. The Company is preparing for product launch through Global Pharmaceuticals, Impax's generic division.

16 Nov 2010

CVS agrees to record fine to settle meth suit

The CVS retail pharmacy chain agreed Thursday to pay a record fine to settle a civil case brought by federal prosecutors who said the company had allowed criminals to buy large amounts of methamphetamine ingredients over the counter.

18 Oct 2010

CVS/pharmacy agrees to pay civil penalties for excessive sales of PSE

CVS/pharmacy today announced agreements with the U.S. Drug Enforcement Administration (DEA) and the U.S. Attorneys' Offices for the Central District of California and the District of Nevada to settle allegations that in 2007 and 2008 certain CVS/pharmacy stores in California and Nevada engaged in unlawful sales of pseudoephedrine (PSE), an ingredient found in popular over-the-counter cold and cough medicines.

15 Oct 2010

Indiana State Legislators holds hearing to improve methamphetamine production

Today, the Indiana State Legislature's Criminal Law and Sentencing Policy Study Committee is holding a hearing on how the state can improve its policies for preventing the illegal diversion of pseudoephedrine (PSE) a key ingredient in leading cold and allergy medicines for methamphetamine production.

9 Sep 2010

Perrigo fourth-quarter fiscal 2010 net sales up 22%

Perrigo Company today announced results for its fourth quarter and full year ended June 26, 2010.

12 Aug 2010

Vyvanse Capsules CII demonstrates significant improvement in adults with ADHD: Phase 3b study

Shire plc, the global specialty biopharmaceutical company, today announced that a Phase 3b study published in Behavioral and Brain Functions found adults with Attention Deficit Hyperactivity Disorder who took once-daily Vyvanse (lisdexamfetamine dimesylate) Capsules CII demonstrated significant improvement in attention.

6 Aug 2010

Study: Drug control efforts have caused a drop in methamphetamine treatment admissions in Mexico

A study published today in the scientific journal Addiction shows that the Mexican government's recent efforts to control the manufacture of methamphetamine have caused a drop in methamphetamine treatment admissions in Mexico and in neighbouring Texas.

6 Aug 2010

AMRI second-quarter adjusted EPS increases to $0.06

AMRI today reported financial and operating results for the second quarter ended June 30, 2010.

5 Aug 2010

Acura Pharmaceuticals reports net loss of $3.2M for second-quarter 2010

Acura Pharmaceuticals, Inc. today reported a second quarter 2010 net loss of $3.2 million or $0.07 per share compared to net loss of $6.5 million, or $0.14 per share for the second quarter of 2009. For the six months ended June 30, 2010, the Company reported a net loss of $7.2 million, or $0.15 per share compared to net loss of $7.8 million, or $0.17 per share for the same period in 2009. At July 29, 2010 we had cash and cash equivalents of approximately $26.5 million with no term indebtedness.

30 Jul 2010

Actient Pharmaceuticals completes transaction to license; acquire six pharmaceutical products from UCB

Actient Pharmaceuticals, LLC ,a portfolio company of GTCR, announced today the company successfully completed a transaction to license and acquire six pharmaceutical products from UCB, Inc., a subsidiary of UCB SA, an international biopharmaceutical company based in Brussels, Belgium.

30 Jul 2010

An overview of heart palpitations from Mayo Clinic

Almost everyone feels occasional heart palpitations -- a change in the heart's rhythm. Palpitations range from what feels like a skip, flip or bump in the heart's rhythm to a sustained, racing heartbeat.

16 Jul 2010

Brand-Nu Laboratories adds Chlophedianol Hydrochloride to API line

Brand-Nu Laboratories, a leading US-based high purity chemical manufacturer and distributor, has introduced Chlophedianol Hydrochloride, also known as Clofedanol Hydrochloride JP, to its product portfolio of active pharmaceutical ingredients (APIs).

12 Jul 2010

GE Healthcare highlights molecular imaging technologies to help clinicians improve patient experiences

Focusing on helping clinicians improve experiences for their patients, GE Healthcare is highlighting an innovative portfolio of molecular imaging technologies and agents at the 57th annual meeting of the Society of Nuclear Medicine, June 5-9, in Salt Lake City.

7 Jun 2010

AMRI first-quarter total revenue down 9% to $49.3 million

AMRI today reported financial and operating results for the first quarter ended March 31, 2010.

5 May 2010

Conservative therapies need to be recommended over routine use of OTC cough/cold products in children

Despite their widespread use by parents and caregivers, over-the-counter (OTC) cold and cough medicines have carried a warning by the FDA since 2008, and still have the potential to cause serious adverse events in infants and children. Conservative therapies, including nasal suctioning, humidification, and nasal saline, should be recommended over routine use of OTC cough/cold products in infants and children, according to a new commentary published in the May 2010 issue of Otolaryngology - Head and Neck Surgery.

4 May 2010

Conservative therapies recommended over routine use of OTC cough/cold products in children

Despite their widespread use by parents and caregivers, over-the-counter cold and cough medicines have carried a warning by the FDA since 2008, and still have the potential to cause serious adverse events in infants and children. Conservative therapies, including nasal suctioning, humidification, and nasal saline, should be recommended over routine use of OTC cough/cold products in infants and children, according to a new commentary published in the May 2010 issue of Otolaryngology - Head and Neck Surgery.

3 May 2010

SCOLR Pharma first-quarter total revenues decrease 3%

SCOLR Pharma, Inc. today reported financial results for the first three months ended March 31, 2010.

30 Apr 2010

Illicit drug haul in Newtown: children exposed to drug fumes

In a shocking report a Newtown, Sydney couple have been arrested and charged with exposing their young children to fumes while they were allegedly cooking drugs in their unit. The police raid also found illegal drugs like amphetamines, pseudoephedrine tablets, marijuana and syringes.

5 Apr 2010